Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival

Cancer Causes and Control

Volumn 21, Issue 10, 2010, Pages 1545-1557

  Kidd, Lacreis R ^a   Brock, Guy N ^b   Vancleave, Tiva T ^a   Benford, Marnita L ^a   Lavender, Nicole A ^a   Kruer, Traci L ^c   Wittliff, James L ^c  

^a University of Louisville School of Medicine   (United States)

^b School of Public Health Information Sciences (SPHIS)   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Angiogenesis; Breast cancer; Disease recurrence; Overall survival; Polymorphisms

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; ESTROGEN RECEPTOR; INTERLEUKIN 10; PROGESTERONE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; VASCULOTROPIN;

ADULT; AGED; ALLELE; ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BREAST NEOPLASMS; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-10; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956948654     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-010-9583-9     Document Type: Article

References (60)

1. JM Wu D Bensen-Kennedy Y Miura, et al. 2005 The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer Biol Blood Marrow Transplant 11 6 455 464 1:CAS:528:DC%2BD2MXmsFKgs78%3D 10.1016/j.bbmt.2005.03. 008 15931634
2. ME Stearns K Fudge F Garcia M Wang 1997 IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression Invasion Metastasis 17 2 62 74 1:CAS:528:DyaK1cXisFCkurg%3D 9561025
3. ME Stearns J Rhim M Wang 1999 Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion Clin Cancer Res 5 1 189 196 1:CAS:528:DyaK1MXhtVShtbg%3D 9918218
4. ME Stearns M Wang 1998 Antimestatic and antitumor activities of interleukin 10 in transfected human prostate PC-3 ML clones: orthotopic growth in severe combined immunodeficient mice Clin Cancer Res 4 9 2257 2263 1:CAS:528:DyaK1cXmslCjsb4%3D 9748147
5. FM Williams LF Cherkas TD Spector AJ MacGregor 2004 A common genetic factor underlies hypertension and other cardiovascular disorders BMC Cardiovasc Disord 4 1 20 10.1186/1471-2261-4-20 15518590
6. D Bello-DeOcampo DJ Tindall 2003 TGF-betal/Smad signaling in prostate cancer Curr Drug Targets 4 3 197 207 1:CAS:528:DC%2BD3sXit1Wht7s%3D 10.2174/1389450033491118 12643470
7. LW Chan MA Moses E Goley, et al. 2004 Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy J Clin Oncol 22 3 499 506 1:CAS:528:DC%2BD2cXptlCrsrY%3D 10.1200/JCO.2004.07.022 14752073
8. W Dummer JC Becker A Schwaaf, et al. 1995 Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma Melanoma Res 5 1 67 68 1:STN:280:DyaK2M3lt1yitg%3D%3D 10.1097/00008390-199502000-00008 7734958
9. JA Foekens HA Peters N Grebenchtchikov, et al. 2001 High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res 61 14 5407 5414 1:CAS:528:DC%2BD3MXnsVCru7o%3D 11454684
10. G Gasparini M Toi M Gion, et al. 1997 Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma J Natl Cancer Inst 89 2 139 147 1:STN:280:DyaK2s7lt1amsw%3D%3D 10.1093/jnci/89.2.139 8998183
11. Y Hasegawa S Takanashi Y Kanehira T Tsushima T Imai K Okumura 2001 Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma Cancer 91 5 964 971 1:CAS:528:DC%2BD3MXitF2jt74%3D 10.1002/1097-0142(20010301)91: 5<964::AID-CNCR1086>3.0.CO;2-O 11251948
12. MC Dickson JS Martin FM Cousins AB Kulkarni S Karlsson RJ Akhurst 1995 Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice Development 121 6 1845 1854 1:CAS:528:DyaK2MXmsVamtr0%3D 7600998
13. X Yang JJ Letterio RJ Lechleider, et al. 1999 Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta EMBO J 18 5 1280 1291 1:CAS:528:DyaK1MXhvFOktLw%3D 10.1093/emboj/18.5.1280 10064594
14. XO Shu YT Gao Q Cai, et al. 2004 Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai breast cancer study Cancer Res 64 3 836 839 1:CAS:528:DC%2BD2cXhtFCgtLs%3D 10.1158/0008-5472.CAN-03- 3492 14871809
15. T Chen D Carter L Garrigue-Antar M Reiss 1998 Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer Cancer Res 58 21 4805 4810 1:CAS:528:DyaK1cXnt1yisro%3D 9809982
16. N Ferrara 2002 VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 10 795 803 1:CAS:528:DC%2BD38XnsVGrtbk%3D 10.1038/nrc909 12360282
17. AJ Guidi SJ Schnitt L Fischer, et al. 1997 Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast Cancer 80 10 1945 1953 1:STN:280:DyaK1c%2FjtFKhtw%3D%3D 10.1002/(SICI)1097-0142(19971115)80:10<1945: :AID-CNCR11>3.0.CO;2-Y 9366297
18. NE Kushlinskii ES Gershtein 2002 Role of vascular endothelial growth factor during breast cancer Bull Exp Biol Med 133 6 521 528 1:CAS:528: DC%2BD38XntFGqs70%3D 10.1023/A:1020259702427 12447454
19. B Linderholm B Lindh B Tavelin K Grankvist R Henriksson 2000 p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma Int J Cancer 89 1 51 62 1:CAS:528:DC%2BD3cXhsVGqsLk%3D 10.1002/(SICI)1097-0215(20000120)89:1<51::AID- IJC9>3.0.CO;2-8 10719731
20. BK Linderholm T Lindahl L Holmberg, et al. 2001 The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer Cancer Res 61 5 2256 2260 1:CAS:528:DC%2BD3MXit1Ogt74%3D 11280795
21. EJ Jacobs HS Feigelson EB Bain, et al. 2006 Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer prevention study II cohort Breast Cancer Res 8 2 R22 10.1186/bcr1400 16613616
22. Q Jin K Hemminki K Enquist, et al. 2005 Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis Clin Cancer Res 11 10 3647 3653 1:CAS:528:DC%2BD2MXktFyrsbs%3D 10.1158/1078-0432. CCR-04-1803 15897560
23. N Kataoka Q Cai W Wen, et al. 2006 Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women Cancer Epidemiol Biomarkers Prev 15 6 1148 1152 1:CAS:528:DC%2BD28Xls1ehsbo%3D 10.1158/1055-9965.EPI-05-0871 16775174
24. P Scheet M Stephens 2006 A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase Am J Hum Genet 78 4 629 644 1:CAS:528: DC%2BD28Xjt1Glsbw%3D 10.1086/502802 16532393
25. http://www.ncbi.nlm.nih.gov/
26. FE McGuigan HM Macdonald A Bassiti, et al. 2007 Large-scale population-based study shows no association between common polymorphisms of the TGFB1 gene and BMD in women J Bone Miner Res 22 2 195 202 1:CAS:528: DC%2BD2sXhvFCgsrY%3D 10.1359/jbmr.061016 17059371
27. BP Schneider GW Sledge Jr 2007 Drug insight: VEGF as a therapeutic target for breast cancer Nat Clin Pract Oncol 4 3 181 189 1:CAS:528: DC%2BD2sXjvV2rurc%3D 10.1038/ncponc0740 17327858
28. BK Linderholm H Hellborg U Johansson, et al. 2009 Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer Ann Oncol 20 10 1639 1646 1:STN:280:DC%2BD1MnjvFyitQ%3D%3D 10.1093/annonc/mdp062 19549711
29. J Faupel-Badger LR Kidd D Albanes J Virtamo K Woodson JA Tangrea 2008 Association of IL-10 polymorphisms with prostate risk and grade of disease Cancer Causes Control 19 2 119 124 10.1007/s10552-007-9077-6 17999153
30. P Krippl U Langsenlehner W Renner, et al. 2003 A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk Int J Cancer 106 4 468 471 1:CAS:528:DC%2BD3sXmtlyqu7Y%3D 10.1002/ijc.11238 12845639
31. M Nakamura Y Abe T Tokunaga 2002 Pathological significance of vascular endothelial growth factor A isoform expression in human cancer Pathol Int 52 5-6 331 339 1:CAS:528:DC%2BD38XmslOgurs%3D 10.1046/j.1440-1827.2002.01367.x 12100515
32. F Wang L Wei L Chen 2000 The relationship between vascular endothelial growth factor, microvascular density, lymph node metastasis and prognosis of breast carcinoma Zhonghua BingLi XueZa Zhi 29 3 172 175 1:STN:280: DC%2BD387jt1ehtg%3D%3D
33. N Ferrara T vis-Smyth 1997 The biology of vascular endothelial growth factor Endocr Rev 18 1 4 25 1:CAS:528:DyaK2sXhsFCiu7s%3D 10.1210/er.18.1.4 9034784
34. Y Chen J Wang MM Fraig, et al. 2001 Defects of DNA mismatch repair in human prostate cancer 1 Cancer Res 61 10 4112 4121 1:CAS:528: DC%2BD3MXktVWqt74%3D 11358834
35. S Eccles L Paon J Sleeman 2007 Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms Clin Exp Metastasis 24 8 619 636 1:CAS:528:DC%2BD1cXhvFGgtrw%3D 10.1007/s10585-007-9123-5 17985200
36. J Kinoshita K Kitamura A Kabashima H Saeki S Tanaka K Sugimachi 2001 Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer Breast Cancer Res Treat 66 2 159 164 1:STN:280:DC%2BD3MzotVWltw%3D%3D 10.1023/A:1010692132669 11437102
37. M Lohela M Bry T Tammela K Alitalo 2009 VEGFs and receptors involved in angiogenesis versus lymphangiogenesis Curr Opin Cell Biol 21 2 154 165 1:CAS:528:DC%2BD1MXksVClurk%3D 10.1016/j.ceb.2008.12.012 19230644
38. D Coradini E Biganzoli C Pellizzaro, et al. 2003 Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen Br J Cancer 89 2 268 270 1:CAS:528:DC%2BD3sXlsVakt7g%3D 10.1038/sj.bjc.6601060 12865915
39. B Linderholm J Bergqvist H Hellborg, et al. 2009 Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor Med Oncol 26 4 480 490 1:CAS:528:DC%2BD1MXhsVKhurrL 10.1007/s12032-008-9157-9 19130322
40. B Linderholm K Grankvist N Wilking M Johansson B Tavelin R Henriksson 2000 Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment J Clin Oncol 18 7 1423 1431 1:CAS:528: DC%2BD3cXivVeisro%3D 10735889
41. L Ryden M Stendahl H Jonsson S Emdin NO Bengtsson G Landberg 2005 Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response Breast Cancer Res Treat 89 2 135 143 1:CAS:528:DC%2BD2MXhtVamsrw%3D 10.1007/s10549-004-1655-7 15692755
42. Sanchez BC, Sundqvist M, Fohlin H et al. (2010) Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. Eur J Cancer. doi: 10.1016/j.ejca.2010. 03.014
43. S Garvin UW Nilsson C Dabrosin 2005 Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells Br J Cancer 93 9 1005 1010 1:CAS:528:DC%2BD2MXhtFChsL3F 10.1038/sj.bjc.6602824 16234819
44. WD Figg EA Kruger DK Price S Kim WD Dahut 2002 Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer Invest New Drugs 20 2 183 194 1:CAS:528:DC%2BD38XkvFersrY%3D 10.1023/A:1015626410273 12099578
45. WW Tan 2006 Novel agents and targets in managing patients with metastatic prostate cancer Cancer Control 13 194 198 16885915
46. FJ Esteva AA Sahin M Cristofanilli, et al. 2005 Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy Clin Cancer Res 11 9 3315 3319 1:CAS:528:DC%2BD2MXjslOqtro%3D 10.1158/1078-0432.CCR-04-1707 15867229
47. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
48. http://snp500cancer.nci.nih.gov/home-1.cfm
49. WM Howell SJ Turner AC Bateman JM Theaker 2001 IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma Genes Immun 2 1 25 31 1:CAS:528:DC%2BD3MXitV2ksL4%3D 10.1038/sj.gene.6363726 11294564
50. DM Turner DM Williams D Sankaran M Lazarus PJ Sinnott IV Hutchinson 1997 An investigation of polymorphism in the interleukin-10 gene promoter Eur J Immuno Genet 24 1 1 8 1:CAS:528:DyaK2sXhsFCjsL0%3D
51. A Ewart-Toland JM Chan J Yuan A Balmain J Ma 2004 A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer Cancer Epidemiol Biomarkers Prev 13 5 759 764 1:CAS:528:DC%2BD2cXkt1Ght7g%3D 15159307
52. M Yokota S Ichihara TL Lin N Nakashima Y Yamada 2000 Association of a T29->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese Circulation 101 24 2783 2787 1:CAS:528:DC%2BD3cXksVCgtbk%3D 10859282
53. AM Dunning PD Ellis S McBride, et al. 2003 A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer Cancer Res 63 10 2610 2615 1:CAS:528:DC%2BD3sXjsleht7w%3D 12750287
54. DJ Grainger K Heathcote M Chiano, et al. 1999 Genetic control of the circulating concentration of transforming growth factor type beta1 Hum Mol Genet 8 1 93 97 1:CAS:528:DyaK1MXoslChsw%3D%3D 10.1093/hmg/8.1.93 9887336
55. D Lambrechts E Storkebaum M Morimoto, et al. 2003 VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death Nat Genet 34 4 383 394 1:CAS:528:DC%2BD3sXmt1Skurk%3D 10.1038/ng1211 12847526
56. M Shahbazi AA Fryer V Pravica, et al. 2002 Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection J Am Soc Nephrol 13 1 260 264 1:CAS:528:DC%2BD38XltV2ntg%3D%3D 11752046
57. S Sfar E Hassen H Saad F Mosbah L Chouchane 2006 Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome Cytokine 35 1-2 21 28 1:CAS:528:DC%2BD28XhtVCrtbbJ 10.1016/j.cyto.2006.07.003 16908180
58. P Krippl U Langsenlehner W Renner, et al. 2003 The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk Cancer Lett 201 2 181 184 1:CAS:528:DC%2BD3sXos1Kmt7k%3D 10.1016/S0304-3835(03)00468-3 14607332
59. W Renner S Kotschan C Hoffmann B Obermayer-Pietsch E Pilger 2000 A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels J Vasc Res 37 6 443 448 1:CAS:528:DC%2BD3MXoslGmsQ%3D%3D 10.1159/000054076 11146397
60. HW Park JE Lee ES Shin, et al. 2006 Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population J Allergy Clin Immunol 117 4 774 779 1:CAS:528: DC%2BD28Xjslels7g%3D 10.1016/j.jaci.2005.12.1328 16630933